← GLP-1 receptor agonists × glycemic control

SynthesisScientific reports2016

Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.

Lin Zhang et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 2016

Randomised comparison

Probably raised glycemic control

+40%+18% to +67%

Bigger than 3 in 10 for glycemic control

As reported

RR 1.40, 95% CI 1.18–1.67

Randomised comparison

Probably raised glycemic control

+30%+12% to +51%

Bigger than 2 in 10 for glycemic control

As reported

RR 1.30, 95% CI 1.12–1.51

Randomised comparison

Probably raised glycemic control

+36%+21% to +53%

Bigger than 3 in 10 for glycemic control

As reported

RR 1.36, 95% CI 1.21–1.53

Randomised comparison

Probably raised adverse events & safety

2.6×1.7× to 4.1×

Bigger than 9 in 10 for adverse events & safety

As reported

RR 2.64, 95% CI 1.69–4.12

+6 more in the walkthrough ↓

Ten numbers in the abstract

the abstract, start to end

… reached HbA1c <7% (57.4% vs. 44.7%; RR, 1.40; 95% CI, 1.18 to 1.67) and …

… reached HbA1c <7% (52.6% vs. 41.6%; RR, 1.30; 95% CI, 1.12 to 1.51) and …

… (55.6%) than with control (43.6%) (RR, 1.36; 95% CI, 1.21 to 1.53).

… the risk of nausea (17.3% vs. 9.0%; RR, 2.64; 95% CI, 1.69 to 4.12), …

… significant differences were noted (RR, 1.48; 95% CI, 0.29 to 7.42)19.

… of those in the control groups (RR, 2.26; 95% CI, 1.56 to 3.28).

… (62.3%) than with control (44.9%) (RR, 2.24; 95% CI, 1.65 to 3.03).

… in control groups (36.9% vs. 32.1%; RR, 1.47; 95% CI, 1.19 to 1.81).

… <7% (68.1% vs. 10.9%, respectively; RR, 4.97; 95% CI, 3.66 to 6.73) and …

… (13.4% vs. 6.9%, respectively; RR, 1.82; 95% CI, 1.44 to 2.31)81113.

← favours treatmentfavours comparator →
could be chance
Glycemic control
RR 1.401.18–1.67
Glycemic control
RR 1.301.12–1.51
Glycemic control
RR 1.361.21–1.53
Adverse events & safety
RR 2.641.69–4.12
Hypoglycaemia
RR 1.480.29–7.42
Glycemic control
RR 2.261.56–3.28
Glycemic control
RR 2.241.65–3.03
Glycemic control
RR 1.471.19–1.81
Glycemic control
RR 4.973.66–6.73
Hypoglycaemia
RR 1.821.44–2.31
MetforminGLP-1 receptor agonistsDPP-4 inhibitorsInsulinGlycemic controlAdverse events & safetyHypoglycaemia

GLP-1 receptor agonists × glycemic controlhelps?replicated

unlikelylikely
0.91not counted

GLP-1 receptor agonists × hypoglycaemiaharms?mixed

unlikelylikely
0.50not counted

Metformin × hypoglycaemiaharms?no deciding trial

unlikelylikely
0.25not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 5

25 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 26742577